Cargando…
Resistance to c-Kit inhibitors in melanoma: insights for future therapies
Mutations activating the receptor tyrosine kinase c-Kit occur commonly in melanomas arising on mucosal membranes and acral skin. Clinical studies have demonstrated that selective inhibition of c-Kit is effective in treating patients with c-Kit mutant gastrointestinal stromal tumors, but c-Kit inhibi...
Autores principales: | Carlino, Matteo S., Todd, Jason R., Rizos, Helen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284619/ https://www.ncbi.nlm.nih.gov/pubmed/25594040 |
Ejemplares similares
-
Kidney‐Derived c‐Kit(+) Cells Possess Regenerative Potential
por: Gomes, Samirah A., et al.
Publicado: (2018) -
KIT and Melanoma: Biological Insights and Clinical Implications
por: Pham, Duc (Daniel) M., et al.
Publicado: (2020) -
Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
por: Gillson, Josef, et al.
Publicado: (2020) -
Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo
por: Posch, Christian, et al.
Publicado: (2016) -
Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling
por: Park, John J., et al.
Publicado: (2022)